ALX Oncology initiated with a Buy at UBS

UBS initiated sum of ALX Oncology (ALXO) with a Buy standing and $6 price target The institution has a imaginable blockbuster programme with a CD47 combo presently successful Phase II for metastatic bosom cancer, the expert tells investors successful a probe note. UBS sees ALX reporting a “robust” dataset successful mid-2027, demonstrating CD47 inhibitor evorpacept’s efficacy successful CD47 precocious and/or HER2+ metastatic bosom crab patients.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected ALXO:

Disclaimer & DisclosureReport an Issue

• ALX Oncology reports Q4 EPS (42c), statement (36c)

• ALXO Earnings this Week: How Will it Perform?

• ALX Oncology terms people raised to $4 from $3 astatine Piper Sandler

• ALX Oncology announces large underwritten nationalist equity offering

• ALX Oncology Highlights Biomarker Data and Cash Position